Detalhe da pesquisa
1.
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Mol Cell;
81(6): 1170-1186.e10, 2021 03 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33571422
2.
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvß6-integrin targeting peptides: considerations on clinical safety profiles.
Eur J Nucl Med Mol Imaging;
2024 May 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38717591
3.
Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy.
Eur J Nucl Med Mol Imaging;
51(6): 1698-1702, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38228970
4.
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020.
Eur J Nucl Med Mol Imaging;
50(7): 2188-2195, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36826478
5.
Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors.
Mol Pharm;
20(5): 2490-2501, 2023 05 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37068305
6.
In Silico and In Vitro Study towards the Rational Design of 4,4'-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker.
Int J Mol Sci;
24(22)2023 Nov 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38003637
7.
Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
Int J Mol Sci;
24(23)2023 Nov 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38069166
8.
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
Br J Cancer;
126(9): 1271-1279, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35013575
9.
Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.
Eur J Nucl Med Mol Imaging;
49(12): 4064-4072, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35771265
10.
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Eur J Nucl Med Mol Imaging;
49(12): 4271-4281, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35767071
11.
Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning.
Eur J Nucl Med Mol Imaging;
49(2): 517-526, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34232350
12.
The added value of PSMA PET/MR radiomics for prostate cancer staging.
Eur J Nucl Med Mol Imaging;
49(2): 527-538, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34255130
13.
Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04.
J Nucl Cardiol;
29(5): 2254-2261, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33860458
14.
Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy.
Mol Ther;
29(2): 788-803, 2021 02 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33068779
15.
Value of PET imaging for radiation therapy.
Strahlenther Onkol;
197(9): 1-23, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34259912
16.
Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients.
Eur J Nucl Med Mol Imaging;
48(2): 543-553, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32725538
17.
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.
Eur J Nucl Med Mol Imaging;
48(9): 2925-2934, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33543325
18.
A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Eur J Nucl Med Mol Imaging;
48(11): 3618-3630, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33954826
19.
Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.
Eur J Nucl Med Mol Imaging;
47(5): 1046-1055, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31811344
20.
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
Eur J Nucl Med Mol Imaging;
47(13): 3047-3057, 2020 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32378020